During this session, we will provide an overview of the evolving science and AD DMT landscape, emphasizing the industry’s commitment to patients amidst decades of difficult scientific progress. The session will also cover challenges throughout the care continuum such as access to screening and diagnosis, coverage of DMTs, patient out-of-pocket costs, and caregiver support. Given the historical challenges with enrollment and retention of minority populations in AD clinical trials, and the broader access and affordability issues faced by those individuals, the session will also explore ways to improve equity in AD care, including industry’s efforts to improve clinical trial diversity.
Sponsored By
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
